

BIOHAZARDOUS AGENT REFERENCE DOCUMENT

Zika virus (ZIKV)

The Biohazardous Agent Reference Document (BARD) is a general guidance resource that reviews and summarizes the nature of a pathogen or biotoxin, and offers safety requirements for work with the agent in the laboratory. The BARD may replace the formal SOPs used in conjunction with some IBC registrations.

The BARD is provided as an additional guidance tool, and is not a substitute for a risk assessment, biosafety training, lab-specific training, or a formal <u>IBC master protocol registration</u>. This document should be readily available in the laboratory, and it is the responsibility of the Laboratory Supervisor or Principal Investigator to ensure that all personnel have read, understood, and signed the document. The BARD is for informational purposes only, and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please consult a health care provider for any medical questions or concerns.

INSTRUCTIONS

- 1. Review the information contained in this document.
- 2. Add any necessary information that is specific to your work in the laboratory (such as strain-specific information). Please be sure that the track changes function is turned on to indicate any changes that you make.
- **3.** Instruct all personnel to review the BARD and sign the last page, indicating that they have read and understood the information.
- 4. Submit the BARD along with your IBC master protocol registration, amendment, or continuing review.



BIOHAZARDOUS AGENT REFERENCE DOCUMENT

Zika virus (ZIKV)

CHARACTERISTICS		
Morphology	Member of the Flaviviridae family, enveloped	
	virus.	
Strain Specific		
Characteristics		

HEALTH HAZARDS			
Host Range	Humans and non-human primates		
Modes of	Blood borne, bite from infected Aedes mosquito,		
Transmission	perinatal, in utero, sexual contact, contact with		
	non-intact skin or mucous membranes		
Signs and	Mostly asymptomatic, but may present with:		
Symptoms	fever, rash, muscle and/or joint pain,		
	conjunctivitis, headache		
Infectious	Unknown		
Dose			
Incubation	3 – 12 days		
Period			

MEDICAL PRECAUTIONS / TREATMENT		
Prophylaxis	None available	
Vaccines	None available	
Treatment	Symptomatic: fever reduction, anti-histamines, pain relief	
Surveillance	Monitor for symptoms and test using serology, RT-PCR, or nucleic acid testing from blood or urine sample	
UVM IBC Requirements	Report any exposures or signs and symptoms to your supervisor	
Additional Medical Precautions	Women who are pregnant or planning on becoming pregnant should be aware that pregnant women infected with Zika can transmit the virus to their fetus, which can result in severe birth defects. Avoid contact with mosquitoes to prevent spreading the virus.	

LABORATORY HAZARDS		
Laboratory Acquired Infections	Accidental infection has occurred in laboratory personnel	
Sources	Infected mosquitos, human or animal blood, body fluids, or tissues, laboratory cultures.	

CONTAINMENT REQUIREMENTS		
BSL - 2	Manipulation of known or potentially infected clinical samples and cell cultures of laboratory	
	adapted strains (RG2)	
BSL - 3		
ABSL - 2	Work with animals infected with risk group 2	
	strains	
ABSL - 3		
Aerosol	Centrifugation, homogenizing, vortexing or	
generating	stirring, changing of animal cages, animal	
activities	surgeries, cell sorting, pipetting, pouring liquids,	
	sonicating, loading syringes	
Primary	Use for aerosol-generating activities, large	
containment	volumes, or high concentrations	
device (BSC)		

EXPOSURE P	ROCEDURES		
Mucous	Flush eyes, mouth or nose for 15 minutes at eyewash		
membrane	station.		
S			
Other	Wash area with soap and water for 15 minutes		
exposures			
Medical	Contact UVMMC Infectious Disease Dept. directly at		
Follow-Up	(802) 847-2700 for immediate assistance. Bring this		
	document with you if seeking medical care.		
Reporting	Report all exposures or near misses to:		
	1. Your immediate Supervisor		
	2. The UVM Biosafety Officer at (802) 777-9471		
	and Risk Management at 6-3242		
	3. Risk Management and Safety;		
	https://www.uvm.edu/riskmanagement/inci		
	dent-claim-reporting-procedures		

PERSONAL PROTECTIVE EQUIPMENT (PPE)			
Minimum PPE	Nitrile gloves, closed toed shoes, lab coat,		
Requirements	appropriate eye/face protection		
Additional	Sharps use strictly limited.		
Precautions			
(Risk			
assessment			
dependent)			



Biosafety Office

BIOHAZARDOUS AGENT REFERENCE DOCUMENT

Zika virus (ZIKV)

VIABILITY		
Disinfection	Susceptible to: 10% bleach, 2% glutaraldehyde, 2% paraformaldehyde, or 70% ethanol with a 10 minute contact time	
Inactivation	Inactivated by heat >60°C, and pH of <4 or >11	
Survival	Unknown	
Outside Host		

SPILL CLEAN UP PROCEDURES		
Small Spill	Notify others working in the lab. Allow aerosols to settle. Don appropriate PPE. Cover area of the spill with paper towels and apply approved disinfectant, working from the perimeter towards the center. Allow 30 minutes of contact time before clean up and disposal. Dispose in double biowaste bags and biobox.	
Large Spill	Inside of a lab:Call UVM Service Operations at656-2560 and press option 1 to speak to adispatcher.Ask them to page Risk Managementand Safety.Outside of a lab:Pull the nearest fire alarm andevacuate the building.Wait out front of thebuilding for emergency responders to arrive.	

REFERENCES			
Emerging	https://wwwnc.cdc.gov/eid/article/22/9/16-		
Infectious	0664 article		
Disease			
BMBL	https://www.cdc.gov/biosafety/publications/b		
	<u>mbl5/</u>		
CDC	https://www.cdc.gov/zika/laboratories/index.ht		
Guidelines	<u>ml</u>		
OSHA Fact	https://www.osha.gov/Publications/OSHA3917.		
Sheet	<u>pdf</u>		

STUDENT / EMPLOYEE NAME	SIGNATURE	DATE

Biosafety Review:

Jeff LaBossiere, Biological Safety Officer

Date

Principal Investigator: _____

IBC Registration #: _____